Clinical Trial Update: Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating durvalumab with tremelimumab versus durvalumab alone and placebo in limited-stage small cell lung cancer patients who have not progress…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-01